# OncoImmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncoimmune

- Industry: Pharmaceuticals
- Headquarters: Rockville, US
- Website: www.oncoimmune.com
- Total disclosed funding: $71M
- Latest round: Series B (Sep 9, 2020)
- Investors on record: 5

## About

Founded in 2000 and based in Maryland, US, OncoImmune, Inc., the developer of CD24Fc, a prophylactic treatment for Graft versus Host Disease (GvHD) of leukemia patients that undergoes hematopoietic stem cell transplantation. The company's pharmaceutical also provides treatment for cancer and autoimmune diseases.

## Funding rounds

- Series B, Sep 9, 2020, $56M — Kaitai Capital, GF Xinde Investment, 3E Bioventures Capital, HM Capital, Greater Bay Area Homeland Investments
- Series A, Jan 12, 2017, $15M — 3E Bioventures Capital

## Investors

- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A, Series B
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B
- Greater Bay Area Homeland Investments — Series B